Browsing publications by Julieann Sludden

Newcastle AuthorsTitleYear
Professor Ruth Plummer
Professor Alan Boddy
Julieann Sludden
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours2011
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Alan Calvert
et al.
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
Dr Johanne Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al.
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer2007
Professor Alan Boddy
Julieann Sludden
Melanie Griffin
Professor Herbie Newell
Professor Stephen O'Brien
et al.
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia2007
Dr Johanne Lee
Julieann Sludden
Professor Alan Boddy
Dr Mark Verrill
Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.2006
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Professor Alan Calvert
Professor Alan Boddy
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
Dr Gareth Veal
Julie Errington
Julieann Sludden
Melanie Griffin
Annie Parry
et al.
Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
123